Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Dose-ranging Study of OPK-88004 Once-a-day Dosing for 16 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

NCT03297398 is registered in ClinicalTrials.gov with OPKO Health, Inc. as lead sponsor.

NCT NCT03297398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03297398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Dose-ranging Study of OPK-88004 Once-a-day Dosing for 16 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Lead sponsor
OPKO Health, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
February 21, 2018
Completion date
June 10, 2019
Enrollment
114 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia